Three’s A Crowd? Celltrion Launches Denosumab In US

Biosimilar Rivals To Prolia And Xgeva Add To A Competitive Market

 
• By Dave Wallace
  
Three biosimilars firms are now challenging Amgen on denosumab (Shutterstock)

More from Biosimilars

More from Products